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Abstract Mitogenic signaling involves protein kinases that
phosphorylate the mitogen-activated protein kinase (MAPK)
activator, MEK. In rats, basal hepatic MEK kinase activity is
low in vivo in both adult rats and late gestation fetal rats, and is
markedly stimulated by intraperitoneal administration of epi-
dermal growth factor (EGF). The level of stimulated MEK
phosphorylating activity is approximately 15 times higher in fetal
liver than in adult liver. To identify regulated forms of the two
categories of MEK kinase, Raf and MEKK, Western immuno-
blotting, immunoprecipitation kinase assays and immunodeple-
tion studies were performed. Western immunoblotting confirmed
that Raf-1, A-Raf, B-Raf, MEKK1 and MEKK2 were present at
similar levels in E19 and adult liver. However, specific
immunoprecipitation kinase assays did not detect any kinases
that could account for marked EGF sensitivity or the higher level
of activity in E19 fetuses. Immunodepletion studies produced a
marked reduction in immunoreactive Raf/MEKK content and
activity, but a minimal decrease in the ability of chromatography
fractions to phosphorylate and activate recombinant MEK-1.
Our results indicate that hepatic, EGF-sensitive MEK kinase
activity may reside with a previously unidentified and physiolo-
gically relevant form of Raf and/or MEKK.
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1. Introduction
Members of the raf family of serine/threonine protein kin-
ases are e¡ectors for the mitogenic actions of GTP-bound
p21ras and related small GTP binding proteins [1^4]. This
observation established the central role of the Raf protein
kinase family in mitogenic signal transduction. Recruitment
of Raf to the cell membrane by GTP-bound Ras is a required
early step in activation of the mitogen-activated protein kinase
(MAPK) pathway [4]. In addition to a role in MAPK signal-
ing, the various forms of Raf may be involved in other aspects
of cell regulation, including the NF-UB pathway [5,6].
The initial identi¢cation of v-raf, the transforming gene of
murine sarcoma virus 3611 [7], was followed by the identi¢-
cation of three cellular homologues, c-raf-1 [8], A-raf [9] and
B-raf [10]. Subsequently, a family of kinases denoted by the
term MEK kinase (MEKK1^4) were identi¢ed and character-
ized [11^13]. MEKK1^4 can activate the c-Jun amino-termi-
nal kinase (JNK) pathway, while MEKK3 may be a physio-
logic regulator for both the JNK and p38 MAPK pathways
[14]. MEKK1 and MEKK2 clearly have signi¢cant relevance
to the regulation of the prototypical MAPKs, ERK1 and
ERK2.
Our laboratory has focused on mitogenic signal transduc-
tion during late gestation liver development in the rat. Our
initial studies on the MAPK signaling pathway showed a low
level of constitutive MAPK activity in fetal liver under basal
conditions [15,16]. We then attempted to de¢ne the stimuli for
fetal hepatic MAPK activation, utilizing in situ activation of
mitogenic pathways by direct intraperitoneal administration
of epidermal growth factor (EGF) to late gestation fetal rats
[17]. As part of these studies, the activation of Raf/MEKK
was examined. Results showed that MEK phosphorylating
activity, measured in FPLC anion exchange (MonoQ) column
fractions, was markedly increased in fetal liver within 15 min
after the intraperitoneal injection of EGF. EGF-mediated ac-
tivation was also seen in adult liver, although the post-EGF
activity recovered after MonoQ chromatography was 15-fold
higher in fetal samples compared to adult samples. The
present studies were undertaken with the aim of characterizing
the Raf and/or MEKK forms responsible for hepatic EGF-
dependent MEK kinase activity in the adult rat and, in par-
ticular, the high level of activity in the late gestation fetus.
2. Materials and methods
2.1. Materials
Human EGF was purchased from PeproTech, Inc. (Rocky Hill,
NJ). Rabbit polyclonal antibodies directed against the carboxy-termi-
nal regions of human Raf-1, A-Raf and B-Raf were obtained from
Santa Cruz Biotechnology, Inc. (Santa Cruz, CA), as were antibodies
against the amino-terminus of human MEKK1 and MEKK2.
Recombinant, histidine-tagged, human ERK-1 and kinase inactive
human MEK-1 were prepared as described previously [17]. Recombi-
nant, histidine-tagged wild type MEK-1 was expressed and puri¢ed as
described by Gardner et al. [18].
2.2. Animals
For fetal studies, timed pregnant Sprague^Dawley rats (Charles
River Breeding Laboratory, Wilmington, MA) were delivered by Ce-
sarean section under pentobarbital anesthesia (50 Wg/g body weight,
intraperitoneal) on day 19 of gestation, term being 21 days. Adult
studies were performed using male Sprague^Dawley rats weighing
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125^175 g. Activation of hepatic EGF signaling was accomplished by
intraperitoneal injection of EGF at a dose of 0.5 Wg/g body weight to
fetuses in situ or to adult male rats. Injection of an equal volume of
vehicle, phosphate-bu¡ered saline, was used as a control.
Liver samples were taken 15 min after saline or EGF injection.
Preparation and fractionation of homogenates by MonoQ ion ex-
change chromatography followed previously described procedures
[16].
2.3. Biochemical analyses
For all immunoprecipitations, antibodies were cross-linked to pro-
tein A-Sepharose CL-4B using the chemical cross-linking reagent,
dimethyl pimelimidate (20 mM in 0.1 M sodium borate, pH 9.0)
[16]. Western immunoblotting of immunoprecipitates was performed
using standard methods with detection by chemiluminescence [16,17].
Immune complex kinase assays for Raf and MEKK isoforms also
employed immunoprecipitation with antibody cross-linked to protein
A-Sepharose beads. Immunoprecipitated complexes were used directly
in a MEK phosphorylating assay that used recombinant, histidine-
tagged, kinase inactive human MEK-1 as substrate. Other assay con-
ditions were identical to those previously employed in our laboratory
[17]. Analysis of MEK phosphorylating activity in fractions derived
from HPLC MonoQ chromatography was carried out under the same
conditions, but without preparatory immunoprecipitation [17]. In
both cases, phospho-MEK-1 was detected by polyacrylamide gel elec-
trophoresis and autoradiography followed by densitometric quanti¢-
cation. Results are expressed as arbitrary absorbance units.
For immunodepletion studies, samples containing 2 mg of rat liver
homogenate protein were precleared with protein A-Sepharose then
incubated at 4‡C for two successive 2 h cycles with a mixture of cross-
linked antibody beads directed at the ¢ve Raf and MEKK forms of
interest. The antibody beads were saved after each cycle and treated
as above for Western immunoblotting. The supernatant that had been
immunodepleted for two cycles was fractionated by MonoQ ion ex-
change chromatography. Fractions were analyzed either for MEK
phosphorylating activity, or for their ability to activate wild type
MEK-1. The latter was determined using a coupled assay that mea-
sured activity as an increase in myelin basic protein (MBP) phosphor-
ylation by recombinant ERK-1. In brief, 17 Wl of each fraction was
mixed with 3 Wl of the recombinant ERK-1 preparation. Samples were
incubated at 30‡C for 30 min followed by the addition of 20 Wl assay
bu¡er (50 mM L-glycerophosphate pH 7.2, 100 WM Na3VO4, 100 nM
microcystin, 20 mM MgCl2, 3 mM EGTA, 200 WM [Q-32P]ATP
(0.25WC/nmol), and recombinant wild type MEK-1). After a 30 min
incubation at 30‡C, 16 Wg of MBP was added. This was followed by
an additional incubation for 15 min at 30‡C. The reaction was
stopped with 10 Wl of 250 mM EDTA. Samples were separated on
a 12% polyacrylamide gel to visualize the phosphorylated MBP. Each
fraction was also run without the addition of recombinant MEK-1 to
control for endogenous MEK-1 activity. The latter proved to be neg-
ligible relative to the added MEK-1.
3. Results and discussion
As we have described previously [17], EGF administration
in vivo to late gestation fetal (E19) or adult rats produced a
maximal level of MEK phosphorylating activity recovered
from MonoQ chromatography that was approximately 15-
fold higher in fetal liver homogenates than in adult liver ho-
mogenates. As a ¢rst step in identifying the speci¢c enzymes
accounting for EGF-responsive MEK phosphorylating activ-
ity, as well as the high level of fetal MEK kinase activity, fetal
and adult liver homogenates were analyzed for Raf and
MEKK content. We focused on Raf-1, A-Raf and B-Raf, as
well as the forms of MEKK that are likely candidates for
regulation of ERK-1 and ERK-2, namely MEKK1 and
MEKK2. Immunoprecipitation of fetal liver homogenates fol-
lowed by Western immunoblotting (Fig. 1) detected immuno-
reactive Raf-1 and A-Raf bands with the expected sizes of
approximately 73 and 65 kDa, respectively [8,9]. In both
cases, smaller forms ranging from 35 to 47 kDa were observed
in fetal samples but not adult samples. The signi¢cance of
these forms is uncertain.
B-Raf was detected in both fetal and adult liver homoge-
nates at the expected size of 95 kDa [19]. MEKK2 was de-
tected as expected at approximately 70 kDa [12]. Again, a
smaller immunoreactive protein of 45 kDa was seen in the
fetal but not the adult sample. Very low levels of immuno-
reactive MEKK1 could be detected at the expected molecular
weight of 195 kDa (not shown). This minimal signal was
present at a higher level in adult liver than in fetal liver. Of
note, the Western immunoblotting results did not demonstrate
the presence of a Raf/MEKK in fetal liver that was absent
from adult liver, or a form that was present in greater
amounts in fetal compared to adult liver.
We next determined the activation states of the aforemen-
tioned forms of Raf and MEKK that were detected by West-
ern immunoblotting. Liver homogenates from fetal and adult
animals that were injected with saline or EGF prior to death
were analyzed for MEK phosphorylating activity. Immuno-
precipitation kinase assays (Fig. 2) revealed that B-Raf was
the predominant immunoprecipitable active MEK kinase in
both fetal and adult liver. However, activity was high under
basal conditions and minimally stimulated by EGF. Immuno-
precipitation with antibodies directed towards Raf-1, A-Raf,
MEKK1 and MEKK2 all resulted in low but detectable MEK
phosphorylation. In no case did we identify the expected ki-
nase showing low activity under basal conditions, marked
responsiveness for EGF, and EGF-stimulated activity in the
fetus that markedly exceeded that seen in the adult.
These results were interpreted as indicating that the afore-
mentioned forms of Raf or MEKK might not account for the
MEK phosphorylating activity recovered from MonoQ chro-
matography. In order to con¢rm this, an immunodepletion
approach was employed. Liver homogenates prepared from
EGF-injected fetuses and an EGF-injected adult were sub-
jected to two 2 h cycles of immunoprecipitation using a com-
bination of immobilized antibodies directed towards Raf-1, A-
Fig. 1. Western immunoblotting for fetal and adult liver Raf-1, A-
Raf, B-Raf and MEKK2. Fetal (F) and adult (A) liver homogenates
were subjected to immunoprecipitation followed by Western immu-
noblotting using antibodies speci¢c for various MEK kinases. Num-
bers to the left of the autoradiograms represent molecular mass in
kDa. Larger numbers designate the apparent size of the expected
forms for each MEK kinase.
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Raf, B-Raf, MEKK1 and MEKK2. Total MEK kinase activ-
ity was determined after both immunoprecipitation cycles.
Results showed that this immunodepletion protocol resulted
in removal of over 90% of the combined, immunoprecipitable
MEK phosphorylating activity (Fig. 3, upper panel). In order
to con¢rm the e¡ectiveness of the immunodepletion process,
the immunodepleted samples were also analyzed by Western
immunoblot. Results (Fig. 3, lower panel) demonstrated that
two cycles of immunodepletion were adequate to reduce levels
of immunoreactive Raf-1, A-Raf, B-Raf and MEKK2 by
more than two thirds.
Control (undepleted) and depleted samples were analyzed
for MEK phosphorylating activity using MonoQ chromatog-
raphy. Results (Fig. 4) showed that immunodepletion resulted
in only a minimal reduction (approximately 10%) in the ac-
tivity recovered following MonoQ chromatography for both
the fetal and adult samples.
These results did not rule out the possibility that the in
vitro MEK phosphorylation we were measuring was at sites
on MEK other than those that are involved in regulating
MEK activity. To address this, the experiment was repeated
using kinase intact MEK-1 as substrate in combination with
recombinant human ERK-1 and MBP. Control (undepleted)
and depleted fetal liver homogenates were fractionated by
MonoQ chromatography. Samples were analyzed for their
ability to activate recombinant MEK-1, as indicated by an
increase in MBP phosphorylation by recombinant ERK-1 in-
cluded in the assay. As a control, each fraction was assayed
for MBP phosphorylation after the addition of MEK-1 plus
ERK-1 versus the addition of ERK-1 alone. Thus, the re-
ported activity was dependent on the activation of exogenous
MEK-1. Results (Fig. 5) showed that total activity across the
pro¢le was decreased by approximately 10% in the immuno-
depleted sample relative to the undepleted sample. This loss of
activity was interpreted as being far less than would be ex-
pected if the measured activity were due to any of the Raf or
MEKK forms being examined.
An alternative explanation consistent with the above results
Fig. 2. Raf and MEKK activities in fetal and adult liver homogenates. Samples from fetal (F) and adult (A) animals injected with saline
(3, open bars) or EGF (+, solid bars) were analyzed by immunoprecipitation kinase assay using antibodies speci¢c for Raf-1, A-Raf, B-Raf,
MEKK1 and MEKK2. A: Autoradiograms showing phosphorylated MEK-1 were obtained after 1 day or 5 days exposure of dried gels.
B: Bars represent the densitometric quanti¢cation of the results shown in A corrected for autoradiography exposure time. Note that all results
are shown to scale.
Fig. 3. Western immunoblot analysis of immunodepleted fetal liver
homogenates. Upper panel: In order to con¢rm the e¡ectiveness of
the immunodepletion protocol, fetal liver homogenates were sub-
jected to three cycles of immunoprecipitation with a mixture of anti-
body beads directed towards Raf-1, A-Raf, B-Raf, MEKK1 and
MEKK2. The sequential immunoprecipitates were analyzed for
MEK phosphorylating activity. Lower panel: The immunodepletion
protocol was repeated with Raf-1, A-Raf, B-Raf and MEKK2 anti-
body beads. Resulting immunoprecipitates were analyzed for immu-
noreactive Rafs and MEKK2. Numbers below each lane correspond
to absorbance of the immunoreactive bands as determined by densi-
tometry.
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was that incorporation of regulated Rafs or MEKKs into
multiprotein complexes interfered with immunoprecipitation.
Given that such complexes would be unlikely to remain intact
after ion exchange chromatography, two experiments were
performed. In the ¢rst, chromatography fractions were sub-
jected to Western immunoblotting for the various forms of
Raf and MEKK. Minimal immunoreactivity was observed
(data not shown), and in no case did immunoreactive species
correspond with MEK kinase activity in the fractions. For the
second experiment, MEK kinase activity eluted from MonoQ
was pooled and subjected to immunoprecipitation with the
panel of antibodies. Results (not shown) demonstrated low
but detectable levels of B-Raf activity that were similar for
both control and EGF-activated preparations. None of the
other antibodies yielded any detectable kinase activity.
Previous studies of MEK kinases in liver have focused on
signal transduction in the adult. We observed that the level of
maximal hepatic MEK kinase activation following EGF in-
jection to a fetus was 15-fold higher than that seen in adult
liver [17]. This led us to hypothesize that known forms of Raf
and/or MEKK are present in greater abundance in fetal liver
than in adult liver. The observation that fetal liver MEK, like
adult liver MEK, was markedly activated by the in vivo ad-
ministration of EGF supported the hypothesis that the main
form(s) of MEK kinase in fetal liver would be EGF-sensitive.
The present studies lead to the conclusion that none of the
currently characterized forms of Raf and MEKK meet our
criteria of higher activity in fetal (relative to adult) homoge-
nates and marked activation in response to EGF. The phys-
iologic relevance of the MEK kinase activity recovered after
MonoQ fractionation of liver homogenates is indicated by in
vivo EGF-mediated activation of MEK-1 and MEK-2 in fetal
and adult liver [17]. By using MEK-1 as a substrate for MEK
kinase activity measurements, we intended to focus on en-
zymes that were relevant to EGF signal transduction through
the MAPK pathway. The demonstration that residual MEK-
phosphorylating activity recovered from MonoQ after immu-
nodepletion could also activate recombinant MEK-1 supports
the relevance of our ¢ndings to the physiologic regulation of
the MAPK signaling pathway in liver.
Our data do not allow conclusions regarding the identity of
the EGF-responsive form(s) of MEK kinase in rat liver. Ex-
amination of the known Rafs and MEKKs shows marked
heterogeneity within the two families. This supports the plau-
sibility of the most obvious interpretation of our ¢ndings
more plausible; that is, the existence of a key signaling kinase
involved in the activation of the hepatic MAP kinase pathway
that has not yet been identi¢ed.
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